Article
Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trial.
Cancer - 15 Mar 2026
Doroshow Deborah B, Shapiro Geoffrey I, Do Khanh, Keedy Vicki L, Mahdi Haider, Sohal Davendra P S, Hafez Navid, LoRusso Patricia M, Cecchini Michael, Sklar Jeffrey, Mortimer Peter, Glover Colin, Moses Jacqueline, Jürgensmeier Juliane M, Eder Joseph P
Abstract excerpt
BACKGROUND: Mutations in genes encoding proteins involved the DNA damage response (DDR) occur in up to 20% of patients with cancer. It is unknown whether poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors, alone or in combination with ATR or AKT inhibitors, have histology-agnostic clinical efficacy in tumors with DDR mutations or PI3K/AKT pathway mutations, respectively. METHODS: The Olaparib...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.